eftilagimod alpha,pembrolizumab
immutep,merck
['eftilagimod', 'head and neck', 'pembro']
douglas adkins, md, presents a randomized phase iib study of eftilagimod alpha &amp; pembrolizumab as first-line treatment of patients w/ recurrent or metastatic head and neck squamous cell carcinoma poster (#78) at 1:15pm at mccormick place in hall a. #asco22 
A National Cancer Institute Comprehensive Cancer Center and member of the National Comprehensive Cancer Network